The nation’s leading sleep medicine group is opposing the use of medical cannabis and synthetic marijuana extracts for the treatment of obstructive sleep apnea (OSA).
Late last year, the Minnesota Department of Health announced that OSA would be added to the state’s medical cannabis program list of chronic medical conditions.
But in a newly published position statement, the American Academy of Sleep Medicine (AASM) took issue with the move, concluding that OSA should be excluded from all state medical cannabis programs lists due to unreliable cannabis delivery methods and “insufficient evidence of treatment effectiveness, tolerability and safety.”
The position statement was published in the April 15 issue of the AASM’s Journal of Clinical Sleep Medicine.
“Until there is sufficient scientific evidence of safety and efficacy, neither marijuana nor synthetic medical cannabis should be used for the treatment of sleep apnea,” AASM president Ilene Rosen, MD, noted in a press release.
... read more at: https://www.medpagetoday.com/psychiatry/sleepdisorders/72379